<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>&lt;Hyunseo Kwon&gt; — HTBAA Fall 2026 :: hyunseo-kwon</title><link>https://pages.htgaa.org/2026b/hyunseo-kwon/index.html</link><description>I’m master student of immunoengineering in Designer cells lab in Yonsei university, Korea kwonhspresent@yonsei.ac.kr Homework, Labs, and Projects See the nav bar on the left to look through my work for How To Biomanufacture Almost Anything (Fall 2026)!</description><generator>Hugo</generator><language>en</language><atom:link href="https://pages.htgaa.org/2026b/hyunseo-kwon/index.xml" rel="self" type="application/rss+xml"/><item><title>Week 1 HW: Final Project Ideas</title><link>https://pages.htgaa.org/2026b/hyunseo-kwon/week-01-hw-project-ideas/index.html</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://pages.htgaa.org/2026b/hyunseo-kwon/week-01-hw-project-ideas/index.html</guid><description>Biomanufacturing a β2m-Engineered HLA-E Peptide-Capture Reagent Panel HTBAA Homework #1 | A discovery tool for cryptic, low-affinity HLA-E ligands&#10;Question Proposal What I will make A 20-member research-use panel of soluble HLA-E complexes, each paired with a different β2-microglobulin (β2m) variant and supplied as a peptide-receptive capture reagent. Living chassis Suspension HEK293 cells that secrete correctly folded, glycosylated HLA-E–β2m complexes into defined medium. Automation AlphaFold/Rosetta triage, robotic liquid handling for expression and peptide-loading screens, and automated sample preparation and data analysis for LC–MS/MS. Meaningful scale 100 discovery kits: 20 variants × 0.10 mg per variant × 100 kits, plus 25% manufacturing overage = 250 mg finished protein. Central hypothesis. Changing the β2m partner can tune HLA-E complex persistence enough to preserve weakly bound peptides that are normally lost during handling. The engineered β2m is a discovery aid—not proof that a recovered peptide is physiologically presented. Every candidate peptide would therefore be re-tested with wild-type human β2m and functional NK-cell assays.</description></item><item><title>Final Project</title><link>https://pages.htgaa.org/2026b/hyunseo-kwon/final-project/index.html</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://pages.htgaa.org/2026b/hyunseo-kwon/final-project/index.html</guid><description/></item></channel></rss>